Jardiance VA Coverage Pathway

How the VA Formulary Handles SGLT2 Inhibitors

The VA National Formulary is managed by the Pharmacy Benefits Management (PBM) Services division and reviewed by the Veterans Affairs Medical Advisory Panel (VA MAP). SGLT2 inhibitors as a class earned broad formulary inclusion after the EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death for empagliflozin versus placebo in patients with type 2 diabetes and established cardiovascular disease [1]. The 2022 VA/DoD Clinical Practice Guideline for type 2 diabetes management lists SGLT2 inhibitors as preferred add-on therapy for patients with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease [2].

Individual VA Medical Centers (VAMCs) and their respective VISNs maintain local formularies that may prefer one SGLT2 inhibitor over another based on contract pricing. Some facilities list dapagliflozin as the default SGLT2 inhibitor. Others stock empagliflozin. A veteran whose provider prescribes Jardiance at a facility that prefers Farxiga will trigger a therapeutic interchange or non-formulary review. This is not a denial. It is a routing step.

The VA PBM issued a national drug monograph update in 2023 acknowledging empagliflozin's expanded indication for heart failure with preserved ejection fraction, based on EMPEROR-Preserved (N=5,988), which showed a 21% reduction in the composite of cardiovascular death or heart failure hospitalization [3]. That expansion strengthened the case for individual access even where dapagliflozin holds formulary preference.

Eligibility Requirements for VA Pharmacy Benefits

Veterans must be enrolled in VA healthcare to access pharmacy benefits. Enrollment alone qualifies a veteran for outpatient prescriptions. The copay depends on Priority Group assignment and whether the medication treats a service-connected condition.

Priority Groups 1 through 6 pay $0 for medications related to service-connected disabilities. For non-service-connected conditions, these groups pay $5 for a 30-day supply of generic medications and $11 for brand-name drugs (2026 copay schedule). Priority Groups 7 and 8 pay the $11 brand-name copay regardless of connection status. Veterans with a 50% or higher service-connected disability rating receive all medications at $0 copay [4].

Empagliflozin prescribed for diabetic nephropathy or heart failure secondary to a service-connected condition qualifies for $0 copay. The prescribing provider documents the connection in the electronic health record. No separate form is needed if the condition already appears in the veteran's Problem List linked to a rated disability.

Step-by-Step Process to Get Jardiance Through the VA

The pathway differs depending on whether your local VAMC stocks empagliflozin on its formulary.

If empagliflozin is on your local formulary: Your provider writes the prescription electronically. The VA pharmacy fills it. You pick it up at the outpatient window or receive it via CMOP mail order within 3 to 5 business days. No prior authorization is required.

If your VAMC prefers a different SGLT2 inhibitor: Your provider submits a non-formulary drug request through CPRS (Computerized Patient Record System). The request goes to the facility's Pharmacy and Therapeutics (P&T) Committee or a delegated clinical pharmacist reviewer. Approval criteria typically include documented intolerance or therapeutic failure on the formulary-preferred agent, or a clinical indication where empagliflozin has stronger evidence than the alternative.

For heart failure with preserved ejection fraction specifically, empagliflozin carries the direct FDA indication from the EMPEROR-Preserved data [3], while dapagliflozin's DELIVER trial (N=6,263) showed a similar 18% reduction in the primary composite endpoint [5]. Both agents perform comparably, so a simple formulary preference switch request may require documentation of adverse effects or drug interactions with the preferred agent rather than superiority arguments.

The non-formulary review takes 5 to 14 business days at most facilities. During this period, the veteran may receive a short bridge supply of the formulary-preferred SGLT2 inhibitor. If the request is denied, veterans can appeal through the facility Patient Advocate or request a second-level review by the VISN Clinical Pharmacy Specialist.

Therapeutic Interchange: What Happens Automatically

VA pharmacies operate under national therapeutic interchange policies. If a veteran transfers from a civilian provider or community care referral with an active empagliflozin prescription, the VA pharmacy may automatically switch to the facility's preferred SGLT2 inhibitor at a therapeutically equivalent dose.

Empagliflozin 10 mg corresponds to dapagliflozin 10 mg for heart failure indications. For diabetes management, empagliflozin 25 mg and dapagliflozin 10 mg produce similar HbA1c reductions of approximately 0.5% to 0.7% [6]. The interchange is clinically appropriate for most patients but should be discussed with the prescriber if the veteran previously failed or had side effects on the substituted agent.

Veterans who want to remain on empagliflozin specifically should inform their VA primary care provider before the first pharmacy encounter so the non-formulary request can be initiated proactively.

Community Care and Dual-Eligible Options

Veterans enrolled in VA healthcare may also receive prescriptions through the MISSION Act community care program. Under community care, a veteran sees an approved civilian provider, and the VA covers the cost including pharmacy. Prescriptions written by community care providers can be filled at VA pharmacies (at VA copay rates) or at civilian retail pharmacies (at the VA's contracted rate through the third-party administrator).

Dual-eligible veterans who carry both VA enrollment and Medicare Part D, Medicaid, or private insurance have additional options. They can fill empagliflozin through their Part D plan using the manufacturer coupon (discussed below) and reserve VA pharmacy benefits for other medications. There is no prohibition on using both systems, though each prescription should be filled through only one channel to avoid duplication alerts [7].

The TRICARE pharmacy benefit also covers empagliflozin for military retirees and dependents. TRICARE formulary placement lists Jardiance as a Tier 3 (non-preferred brand) medication with a $60 copay at retail and $44 through TRICARE mail order (Express Scripts). Active-duty service members pay $0 across all tiers.

Manufacturer Coupon and Patient Assistance Programs

Boehringer Ingelheim offers the Jardiance Savings Card for commercially insured patients, reducing out-of-pocket costs to as low as $10 per month for eligible fills [8]. This card cannot be used with federal healthcare programs including VA, TRICARE, or Medicare Part D. It applies only to commercial insurance claims processed at retail pharmacies.

For uninsured patients or those facing coverage gaps, the Boehringer Ingelheim Cares Foundation provides free medication to qualifying individuals with household income at or below 400% of the federal poverty level. Veterans not enrolled in VA healthcare (or those in Priority Groups 7-8 facing copay burdens for non-connected conditions) may qualify [8].

The cost differential is significant. The average civilian cash price of empagliflozin exceeds $680 monthly. The VA copay caps at $11. For the vast majority of veterans, VA pharmacy is the most cost-effective pathway. The manufacturer coupon becomes relevant only when a veteran uses a private insurance plan as primary.

Clinical Scenarios That Strengthen a Non-Formulary Request

Providers writing non-formulary requests for empagliflozin should document specific clinical rationale. The following scenarios carry weight with P&T reviewers:

Documented adverse reaction to dapagliflozin. If the veteran experienced genital mycotic infections, volume depletion, or euglycemic diabetic ketoacidosis on the formulary-preferred agent, switching within the SGLT2 class to empagliflozin is reasonable. Cross-class reaction rates for genital infections are approximately 60-70%, meaning a trial of a different SGLT2 inhibitor may still succeed [9].

Drug interaction concern. Empagliflozin and dapagliflozin share similar metabolic profiles (primarily UGT-mediated glucuronidation), so true pharmacokinetic interaction differences are rare. The stronger argument involves differing renal dosing thresholds. Empagliflozin's heart failure indication carries no eGFR floor for initiation as of current labeling, while prescribing practices for dapagliflozin in CKD follow the DAPA-CKD protocol down to eGFR 25 mL/min/1.73m² [10].

Specific trial evidence. For patients with type 2 diabetes and established atherosclerotic cardiovascular disease, EMPA-REG OUTCOME remains the landmark trial. The 14% reduction in the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (HR 0.86 to 95% CI 0.74-0.99) predated dapagliflozin's DECLARE-TIMI 58 results by three years [1]. While DECLARE showed no reduction in MACE, it did reduce heart failure hospitalizations by 27% [11]. Clinicians can argue trial-specific concordance with their patient's risk profile.

Patient preference and adherence history. The VA recognizes patient-centered care principles. If a veteran has been stable on empagliflozin through a civilian provider or community care pathway for 6+ months, disrupting that regimen introduces unnecessary risk. Medication reconciliation at enrollment should preserve effective therapies where possible.

Mail-Order Pharmacy and 90-Day Supplies

The VA's CMOP system ships medications directly to veterans' homes at no additional shipping cost. A 90-day supply of empagliflozin through CMOP costs the same copay as a single 30-day fill ($0 or $11 depending on Priority Group and service connection). This represents the most economical option available.

To set up CMOP delivery, veterans can request mail-order preference through My HealtheVet, by calling the VA pharmacy automated refill line (1-877-298-8455), or by informing their provider during the clinic visit. Refills process automatically 10 days before the supply runs out. Veterans can pause or cancel automatic refills at any time.

For veterans living in rural areas far from a VAMC, CMOP mail order eliminates the pharmacy access barrier entirely. Combined with telehealth visits for ongoing diabetes or heart failure management, the entire care pathway can be managed remotely.

Comparing VA Coverage to Civilian Insurance Pathways

A veteran choosing between VA pharmacy and a private insurance plan should consider total out-of-pocket exposure. Commercial plans with the manufacturer coupon may yield $10/month costs, but the coupon expires after 24 months or when a coverage maximum is reached. Without the coupon, Tier 3 brand copays on commercial plans average $45 to $75 monthly.

Medicare Part D plans place empagliflozin on Tier 4 (non-preferred specialty) or Tier 3, with copays of $42 to $100 before reaching the coverage gap. The Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) limits total Part D drug spending, which benefits veterans taking multiple brand-name medications [12].

The VA's $11 maximum copay per 30-day supply (or per 90-day CMOP fill) with no annual cap, no deductible, and no coverage gap makes it the clear winner for most veterans. The only scenario where civilian coverage might be preferable is when a veteran has already hit their Part D $2,000 cap from other medications and empagliflozin would then be $0 through Part D for the rest of the year.

What to Do If Your Request Is Denied

A denied non-formulary request is not the end of the road. Veterans have several escalation paths:

First, ask the prescribing provider to review the denial rationale and resubmit with additional documentation. Common denial reasons include insufficient trial of the formulary-preferred agent or incomplete documentation of adverse effects.

Second, contact the Patient Advocate at your facility. Advocates can support communication between the veteran, provider, and pharmacy reviewers.

Third, request a VISN-level pharmacy review. Each VISN has a Clinical Pharmacy Program Manager who can override facility-level decisions when clinical justification is compelling.

Fourth, file a complaint through the VA's toll-free patient line (1-800-488-8244) if the denial appears inconsistent with published VA/DoD treatment guidelines recommending SGLT2 inhibitors for the veteran's specific condition.

Dr. Chester Good, former Director of VA Pharmacy Benefits Management, stated in a 2021 Federal Practitioner commentary: "The VA formulary system is designed to ensure access to the most clinically appropriate medications, not to restrict access. Non-formulary requests exist precisely for cases where the standard formulary option does not meet an individual veteran's needs" [13].

The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors independent of HbA1c for patients with type 2 diabetes and established heart failure or CKD, noting that "the cardiovascular and kidney benefits of these agents are established for the class as a whole" [14]. This guideline language supports formulary access to any SGLT2 inhibitor, including empagliflozin, when the preferred agent is unsuitable.